NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $48.20 -0.60 (-1.23%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$45.22▼$48.7050-Day Range$45.50▼$50.3352-Week Range$26.65▼$50.66Volume92,928 shsAverage Volume51,407 shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$59.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Belite Bio alerts: Email Address Belite Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside22.4% Upside$59.00 Price TargetShort InterestHealthy0.96% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.19) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 starsMedical Sector685th out of 910 stocksPharmaceutical Preparations Industry317th out of 426 stocks 2.5 Analyst's Opinion Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 3 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.96% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Belite Bio has recently decreased by 9.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLTE. Previous Next 2.5 News and Social Media Coverage News SentimentBelite Bio has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Belite Bio this week, compared to 2 articles on an average week.Search Interest1 people have searched for BLTE on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.19) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -40.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -40.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 12.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Belite Bio Stock (NASDAQ:BLTE)Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Read More BLTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLTE Stock News HeadlinesSeptember 6 at 1:24 AM | nz.finance.yahoo.comBelite Bio Inc (D01.DU)September 3, 2024 | finance.yahoo.comBelite Bio to Participate in Three Upcoming Investor ConferencesSeptember 7, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.September 2, 2024 | markets.businessinsider.comBelite Bio Appoints Hendrik Scholl As Chief Medical OfficerSeptember 1, 2024 | globenewswire.comBelite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical OfficerSeptember 1, 2024 | americanbankingnews.comBelite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeAugust 16, 2024 | markets.businessinsider.comBelite Bio, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical TrialsAugust 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Strong Clinical Progress and Financial StabilitySeptember 7, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.August 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio Amidst Promising Developments for TinlarebantAugust 13, 2024 | seekingalpha.comBelite Bio, Inc (BLTE) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.comBelite Bio, Inc 2024 Q2 - Results - Earnings Call PresentationAugust 11, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAugust 9, 2024 | globenewswire.comBelite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAugust 8, 2024 | globenewswire.comBelite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceAugust 5, 2024 | globenewswire.comBelite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial ResultsAugust 3, 2024 | nz.finance.yahoo.comBELITE BIO INC.SP.ADR/1 (D01.BE)June 12, 2024 | globenewswire.comBelite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in JapanSee More Headlines Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$59.00 High Stock Price Target$60.00 Low Stock Price Target$57.00 Potential Upside/Downside+22.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.84% Return on Assets-37.97% Debt Debt-to-Equity RatioN/A Current Ratio24.76 Quick Ratio24.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book12.89Miscellaneous Outstanding Shares29,794,000Free Float25,834,000Market Cap$1.44 billion OptionableNot Optionable Beta-1.49 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Yu-Hsin Lin M.B.A. (Age 45)Ph.D., Chairman of the Board of Directors & CEO Mr. Hao-Yuan Chuang C.F.A. (Age 39)F.R.M., M.B.A., CFO & Director Dr. Nathan L. Mata Ph.D. (Age 57)Chief Scientific Officer Key CompetitorsOrganon & Co.NYSE:OGNBridgeBio PharmaNASDAQ:BBIONuvalentNASDAQ:NUVLMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Sold 1,389 shares on 8/19/2024Ownership: 0.025%Armistice Capital LLCBought 148,000 shares on 8/15/2024Ownership: 0.497%View All Institutional Transactions BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $45.75 on January 1st, 2024. Since then, BLTE stock has increased by 5.4% and is now trading at $48.20. View the best growth stocks for 2024 here. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an IPO on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. Who are Belite Bio's major shareholders? Top institutional shareholders of Belite Bio include Armistice Capital LLC (0.50%) and Point72 Asset Management L.P. (0.02%). How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLTE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.